• Something wrong with this record ?

Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis

N. Harris, J. Koppel, F. Zsila, S. Juhas, G. Il'kova, FY. Kogan, O. Lahmy, G. Wildbaum, N. Karin, R. Zhuk, P. Gregor,

. 2016 ; 65 (4) : 285-94. [pub] 20160121

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2002-01-01 to 1 year ago

OBJECTIVE AND DESIGN: Elucidate the mechanism of action of the small molecule inhibitor of protein binding to glycosaminoglycans, RX-111 and assay its anti-inflammatory activity in animal models of inflammatory disease. MATERIALS: The glycosaminoglycan, heparin, was used in the mechanism of action study of RX-111. Human T lymphocytes and umbilical vein endothelial cells were used to assay the in vitro activity of RX-111. Mouse and rat models of disease were used to assay the anti-inflammatory activity of RX-111 in vivo. METHODS: Circular dichroism and UV/Vis absorption spectroscopy were used to study the binding of RX-111 to the glycosaminoglycan, heparin. T lymphocyte rolling on endothelial cells under shear flow was used to assay RX-111 activity in vitro. Delayed-type hypersensitivity (DTH) and tri-nitrobenzene sulfonic acid (TNBS)-induced colitis in mice and experimental autoimmune encephalomyelitis (EAE) in rats were used to assay anti-inflammatory activity of RX-111 in vivo. RESULTS: RX-111 was shown to bind directly to heparin. It inhibited leukocyte rolling on endothelial cells under shear flow and reduced inflammation in the mouse model of DTH. RX-111 was efficacious in the mouse model of inflammatory bowel disease, TNBS-induced colitis and the rat model of multiple sclerosis, EAE. CONCLUSIONS: RX-111 exercises its broad spectrum anti-inflammatory activity by a singular mechanism of action, inhibition of protein binding to the cell surface GAG, heparan sulfate. RX-111 and related thieno[2,3-c]pyridine derivatives are potential therapeutics for the treatment of inflammatory and autoimmune diseases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000606
003      
CZ-PrNML
005      
20170118112119.0
007      
ta
008      
170103s2016 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00011-016-0915-4 $2 doi
024    7_
$a 10.1007/s00011-016-0915-4 $2 doi
035    __
$a (PubMed)26794621
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Harris, Nicholas $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. nharris@braude.ac.il. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude Academic College of Engineering, 21982, Karmiel, Israel. nharris@braude.ac.il.
245    10
$a Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis / $c N. Harris, J. Koppel, F. Zsila, S. Juhas, G. Il'kova, FY. Kogan, O. Lahmy, G. Wildbaum, N. Karin, R. Zhuk, P. Gregor,
520    9_
$a OBJECTIVE AND DESIGN: Elucidate the mechanism of action of the small molecule inhibitor of protein binding to glycosaminoglycans, RX-111 and assay its anti-inflammatory activity in animal models of inflammatory disease. MATERIALS: The glycosaminoglycan, heparin, was used in the mechanism of action study of RX-111. Human T lymphocytes and umbilical vein endothelial cells were used to assay the in vitro activity of RX-111. Mouse and rat models of disease were used to assay the anti-inflammatory activity of RX-111 in vivo. METHODS: Circular dichroism and UV/Vis absorption spectroscopy were used to study the binding of RX-111 to the glycosaminoglycan, heparin. T lymphocyte rolling on endothelial cells under shear flow was used to assay RX-111 activity in vitro. Delayed-type hypersensitivity (DTH) and tri-nitrobenzene sulfonic acid (TNBS)-induced colitis in mice and experimental autoimmune encephalomyelitis (EAE) in rats were used to assay anti-inflammatory activity of RX-111 in vivo. RESULTS: RX-111 was shown to bind directly to heparin. It inhibited leukocyte rolling on endothelial cells under shear flow and reduced inflammation in the mouse model of DTH. RX-111 was efficacious in the mouse model of inflammatory bowel disease, TNBS-induced colitis and the rat model of multiple sclerosis, EAE. CONCLUSIONS: RX-111 exercises its broad spectrum anti-inflammatory activity by a singular mechanism of action, inhibition of protein binding to the cell surface GAG, heparan sulfate. RX-111 and related thieno[2,3-c]pyridine derivatives are potential therapeutics for the treatment of inflammatory and autoimmune diseases.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika $x farmakologie $x terapeutické užití $7 D000893
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kolitida $x chemicky indukované $x farmakoterapie $x imunologie $7 D003092
650    _2
$a encefalomyelitida autoimunitní experimentální $x farmakoterapie $x imunologie $7 D004681
650    _2
$a heparitinsulfát $x metabolismus $7 D006497
650    _2
$a endoteliální buňky pupečníkové žíly (lidské) $x účinky léků $x imunologie $7 D061307
650    _2
$a lidé $7 D006801
650    _2
$a pozdní přecitlivělost $x chemicky indukované $x farmakoterapie $x imunologie $7 D006968
650    _2
$a rolling leukocytů $x účinky léků $7 D036904
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a encefalitogenní základní proteiny $x imunologie $7 D004676
650    _2
$a oxazolon $7 D010081
650    _2
$a pyridiny $x farmakologie $x terapeutické užití $7 D011725
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani inbrední LEW $7 D011917
650    _2
$a T-lymfocyty $x účinky léků $x imunologie $7 D013601
650    _2
$a thiofeny $x farmakologie $x terapeutické užití $7 D013876
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kyselina trinitrobenzensulfonová $7 D014302
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Koppel, Juraj $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
700    1_
$a Zsila, Ferenc $u Biomolecular Self-Assembly Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Budapest, Hungary.
700    1_
$a Juhas, Stefan $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. Institute of Animal Physiology and Genetics of the ASCR, v. v. i., Rumburská 89, 277 21, Liběchov, Czech Republic.
700    1_
$a Il'kova, Gabriela $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. GYN-FIV a.s., Záhradnícka 42, 821 085, Bratislava, Slovakia.
700    1_
$a Kogan, Faina Yurgenzon $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Lahmy, Orly $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Wildbaum, Gizi $u Department of Immunology, Rappaport Institute, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
700    1_
$a Karin, Nathan $u Department of Immunology, Rappaport Institute, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
700    1_
$a Zhuk, Regina $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Gregor, Paul $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. paul@gismotherapeutics.com. GISMO Therapeutics Inc., A253 ASTECC-UK, Lexington, KY, 40506, USA. paul@gismotherapeutics.com.
773    0_
$w MED00002242 $t Inflammation research official journal of the European Histamine Research Society ... [et al.] $x 1420-908X $g Roč. 65, č. 4 (2016), s. 285-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26794621 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170118112226 $b ABA008
999    __
$a ok $b bmc $g 1179746 $s 961173
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c 4 $d 285-94 $e 20160121 $i 1420-908X $m Inflammation research $n Inflamm Res $x MED00002242
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...